{"id":"W3046175925","doi":"10.1007/s40266-020-00783-w","title":"Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet","year":2020,"lang":"en","type":"article","venue":"Drugs & Aging","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Astellas Pharma Global Development; Astellas Pharma","keywords":"Tolerability; Overactive bladder; Mirabegron; Medicine; Placebo; Urology; Pharmacotherapy; Double blind; Randomized controlled trial; Tolterodine; Double blind study; Pillar; Adverse effect; Internal medicine; Anesthesia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002078034,0.0002513771,0.001281723,0.00009879936,0.0001126796,0.00004681819,0.0001526739,0.00004728443,0.00003283119],"category_scores_gemma":[0.0004195626,0.0001561078,0.00008667688,0.0003817697,0.0001346141,0.0001563026,0.0001574361,0.0005515574,0.000003352661],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006760197,"about_ca_system_score_gemma":0.00013325,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003443527,"about_ca_topic_score_gemma":0.0002457932,"domain_scores_codex":[0.9964067,0.001062259,0.0008119883,0.0006113861,0.0007886955,0.0003189977],"domain_scores_gemma":[0.9970781,0.00189183,0.0002520955,0.0004318137,0.0001706112,0.0001756154],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7970347,0.003675638,0.05958754,0.00001986337,0.0007242087,0.00006297656,0.1365999,0.00004502725,0.00001333751,8.149597e-7,0.00003067241,0.002205324],"study_design_scores_gemma":[0.9058535,0.003932734,0.06499683,0.00007441111,0.0004131138,8.688658e-7,0.02355441,0.0009289329,0.00003124401,0.000008874727,0.00005664788,0.0001484654],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866698,0.0001414357,0.000008131957,0.001246445,0.00003001188,0.01116058,0.0000791006,0.00002551409,0.0006389153],"genre_scores_gemma":[0.9994209,0.00004202831,0.00002406137,0.0001524019,0.00006660778,0.0001674893,0.00007230998,0.00002688662,0.00002732966],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1130454,"threshold_uncertainty_score":0.6365893,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02976601168245524,"score_gpt":0.3183078597755697,"score_spread":0.2885418480931145,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}